Novo Nordisk A/S Stock News

These stocks are worth buying whether or not a recession is coming.

These stocks are worth buying whether or not a recession is coming.

Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.

Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.

Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.

Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.

Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.

Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.

Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.

VANCOUVER, British Columbia, June 28, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) reports that all resolutions propos

Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of

The appointment of a new top executive clearly meets with investor approval.